Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs
DOI:
https://doi.org/10.53366/jimki.vi.961Keywords:
autoimmune, psoriasis, TYK2InhibitorAbstract
Psoriasis is a chronic immune-mediated disease affecting 1–3% of the population worldwide and often impairs quality of life, with moderate-to-severe cases requiring systemic therapy. Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor that modulates IL-23, IL-12, and type I interferon pathways, has emerged as a promising oral therapy. However, trial findings remain inconsistent, highlighting the need for systematic evaluation of its efficacy and safety versus placebo. A comprehensive literature search of PubMed, Scopus, Scilit, and ScienceDirect was performed to identify randomized controlled trials published up to 2025 comparing deucravacitinib with placebo in psoriasis. Risk of bias was assessed using the Cochrane RoB 2.0 tool, and meta-analysis was conducted with Rstudio with random effect model and REML estimator. Seven RCTs (n = 3,014) were included. Deucravacitinib significantly improved PASI-75 (OR = 9.85; 95% CI 5.11–19.01; p < 0.0001), PASI-90 (OR = 14.29; 95% CI 9.14–22.35; p < 0.0001), and PASI-100 (OR = 12.03; 95% CI 5.55–26.09; p < 0.0001), as well as sPGA 0/1 (OR = 14.28; 95% CI 9.30–23.62; p < 0.0001). Quality-of-life outcomes also improved: PSSD-0 (OR = 7.60; 95% CI 2.73–21.16; p = 0.0001) and DLQI 0/1 (OR = 6.27; 95% CI 4.68–8.41; p < 0.0001). Upper respiratory tract infection and acne were more frequent with deucravacitinib, while other adverse events were comparable to placebo. Meta-regression showed dose dependence for DLQI 0/1 (p = 0.02) and PSSD-0 (p = 0.01), but not for adverse events. Deucravacitinib demonstrates significant efficacy and acceptable safety in psoriasis treatment. Long-term studies are warranted to confirm its sustained safety profile.
Keywords: Deucravacitinib, Psoriasis, TYK2 Inhibitor, Efficacy
References
1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6.
2. Jiang Z, Zeng G, Dai H, Bian Y, Wang L, Cao W, et al. Global, regional and national burden of liver cancer 1990–2021: a systematic analysis of the global burden of disease study 2021. BMC Public Health. 2025 Mar 8;25(1):931.
3. Kristina SA, Endarti D, Aditama H, Nisrina Salsabila N. The medical cost of liver cancer in a referral hospital in Indonesia during 2020. J Appl Pharm Sci. 2021 Dec 5;
4. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018 Mar;391(10127):1301–14.
5. WANG XJ, XU YH, YANG GC, CHEN HX, ZHANG P. Tetramethylpyrazine inhibits the proliferation of acute lymphocytic leukemia cell lines via decrease in GSK-3?. Oncol Rep. 2015 May;33(5):2368–74.
6. Montani F, Bianchi F. Circulating Cancer Biomarkers: The Macro-revolution of the Micro-RNA. EBioMedicine. 2016 Mar;5:4–6.
7. Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci. 2021 Aug 29;22(17):9380.
8. Sugawara Y, Hibi T. Recent trends and new developments in liver transplantation. Biosci Trends. 2024 Jun 30;18(3):2024.01176.
9. Murphy N, Carreras-Torres R, Song M, Chan AT, Martin RM, Papadimitriou N, et al. Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. Gastroenterology. 2020 Apr;158(5):1300-1312.e20.
10. DeClerck YA. Envision the future of precision medicine in pediatric cancer. Cancer Cell. 2024 Feb;42(2):177–9.
11. Bolkvadze R, Kashibadze K, Nakashidze M, Mikeladze L, Beridze D, Berdize S. Incidence and Risk Factor of Hepatocellular Carcinoma Recurrence After Liver Transplant: Results From a Single Clinic. Experimental and Clinical Transplantation. 2024 Jan;22(Suppl 1):256–62.
12. Milana F, Polidoro MA, Famularo S, Lleo A, Boldorini R, Donadon M, et al. Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. Cancers (Basel). 2023 Jan 13;15(2):508.
13. Györi GP, Pereyra D, Rumpf B, Hackl H, Köditz C, Ortmayr G, et al. The von Willebrand Factor Facilitates Model for End?Stage Liver Disease–Independent Risk Stratification on the Waiting List for Liver Transplantation. Hepatology. 2020 Aug 23;72(2):584–94.
14. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018 Feb;68(2):268–79.
15. Gong WF, Zhong JH, Lu SD, Wang XB, Zhang QM, Ma L, et al. Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Oncotarget. 2017 Feb 28;8(9):15047–56.
16. ZHANG H, ZHOU Y, YUAN G, ZHOU G, YANG D, ZHOU Y. Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis. Mol Clin Oncol. 2015 Nov;3(6):1239–47.
17. Linye H, Zijing X, Xiaoyun Z, Zhihui L, Tianfu W, Chuan L. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial. Int J Surg. 2023 Oct 1;109(10):3032–41.
18. Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma. Ann Surg. 2015;261(1):56–66.
19. Huang G, Li P peng, Lau WY, Pan Z ya, Zhao L hao, Wang Z guang, et al. Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: A randomized controlled trial. Ann Surg. 2018;268(6):943–54.
20. Wang MD, Li C, Liang L, Xing H, Sun LY, Quan B, et al. Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Oncologist. 2020 Oct 1;25(10):e1541–51.
21. Chen XX, Cheng JW, Huang A, Zhang X, Wang J, Fan J, et al. The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. Onco Targets Ther. 2017 Nov;Volume 10:5363–75.
22. Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017;9(5):227.
23. Lam YF, Yuen MF, Seto WK, Lai CL. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep. 2011 Dec;10(4):235-243. doi: 10.1007/s11901-011-0109-z. Epub 2011 Aug 9. PMID: 22131901; PMCID: PMC3210946.
24. Liu, Z., Zhao, Z., Ma, X. et al. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. BMC Gastroenterol 23, 384 (2023). https://doi.org/10.1186/s12876-023-03027-4
25. Jung WJ, Jang JY, Park WY, Jeong SW, Lee HJ, Park SJ, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Baymbajav B. Effect of tenofovir on renal function in patients with chronic hepatitis B. Medicine (Baltimore). 2018 Feb;97(7):e9756. doi: 10.1097/MD.0000000000009756. PMID: 29443737; PMCID: PMC5839852.
26. Luo Q, Deng Y, Cheng F, Kang J, Zhong S, Zhang D, Zeng W. Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis. Medicine (Baltimore). 2016 Dec;95(50):e5578. doi: 10.1097/MD.0000000000005578. PMID: 27977591; PMCID: PMC5268037.
27. Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med. 2016 Sep;4(18):334. doi: 10.21037/atm.2016.09.19. PMID: 27761438; PMCID: PMC5066043.
Published
Issue
Section
License
Copyright (c) 2025 Rizky Putera, Livilia Abigail Onggowasito, Erlangga Masykur Kynaya
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.